| Catalog Number |
1000100 |
| Medical Device Problem Code |
Adverse Event Without Identified Device or Use Problem (2993)
|
| Health Effect - Clinical Codes |
Hematoma (1884); Hemorrhage/Blood Loss/Bleeding (1888)
|
| Date of Event |
03/19/2026
|
|
Type of Reportable Event
|
Death
|
|
Additional Manufacturer Narrative
|
|
This is one of two related reports.The is report represents the impella 5.5 and another report was submitted to represent the impella cp.This report is being submitted pursuant to the provisions of 21 cfr, part 803.This report may be based on information which has not been investigated or verified prior to the required reporting date.This report does not reflect a conclusion by abiomed inc, or its employees that the report constitutes an admission that the product, abiomed inc, or its employees caused or contributed to the potential event described in this report.If information is obtained that was not available for the initial report, a follow-up report will be filed as appropriate.
|
| |
|
Event or Problem Description
|
|
Clinical narrative: an impella 5.5 device was inserted via the right axillary artery in a 67-year-old male patient presenting with acute myocardial infarction complicated by cardiogenic shock (ami/cgs), scai shock stage e.The patient¿s comorbidities were unknown.The patient required six units of packed red blood cells following escalation of support.Blood loss was attributed to a disconnected arterial line that leaked onto the floor and a jackson-pratt drain that pulled more than 800 ml from the axillary pocket.Another contributing factor was a loose arterial-line connection.The patient was overly anticoagulated prior to the procedure.A chest-wall hematoma was noted; the physician stated it ¿looked fine¿ and elected to continue heparin.An additional unit of blood was administered.Care was eventually withdrawn, and the patient expired.The reported major bleed and hematoma requiring blood transfusion is consistent with access-site and peri-procedural bleeding complications in the setting of anticoagulation and mechanical circulatory support.The device will be conservatively reported for death; however, the death is most likely attributable to the severity of the underlying ami/cgs and profound hemodynamic deterioration associated with scai shock stage e.
|
| |
|
Additional Manufacturer Narrative
|
|
Added: d3.Corrected: d4 (serial).Asae/ major bleed/ hematoma : the cause of the access site adverse event was use related as the blood loss was attributed to procedural/line management factors (a-line disconnection) and access-site/pocket drainage requiring transfusion support.
|
| |
|
Search Alerts/Recalls
|